AIF1 and neoplasm: When we looked at microglia/macrophage activation, we did not observe any difference between vehicle and TMZ-treated Gli36ΔEGFR-1 tumors (Figure 3E); after treatment with TMZ plus MET no signs of tumor or Iba1 markers were visible.